5:56 PM
 | 
Jun 19, 2013
 |  BC Extra  |  Company News

Priority Review for Paladin's leishmaniasis compound

Paladin Labs Inc. (TSX:PLB) said FDA accepted and granted Priority Review to an NDA for Impavido miltefosine to treat leishmaniasis. The PDUFA date is Dec. 19. Paladin said it...

Read the full 139 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >